About Gastrointestinal Disorders
Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota. Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn’s disease, ulcerative colitis, and peptic ulcers.
Technavio’s analysts forecast the global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Gastrointestinal Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Johnson & Johnson
• Takeda
• Allergan
• UCB
Other prominent vendors
• 4SC
• Ajinomoto Pharmaceuticals
• Alfa Wassermann
• Alizyme
• Amgen
• Anterogen
• Ardelyx
• Arena Pharmaceuticals
• Astellas
• AstraZeneca
• Astellas Pharma
• Avaxia Biologics
• Biogen Idec
• BioLineRx
• Celgene
• ChemoCentryx
• Cosmo Pharmaceuticals
• Drais Pharmaceuticals
• Eisai
• Eli Lilly
• Enlivex Therapeutics
• F. Hoffmann-La Roche
• Ferring Pharmaceuticals
• FF Pharma
• Galapagos
• Gilead Sciences
• GlaxoSmithKline
• Hutchison Medi Pharma
• Immune Pharmaceuticals
• InDex Pharmaceuticals
• Ironwood Pharmaceuticals
• Kaken Pharmaceutical
• Kang Stem Biotech
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
• Lexicon Pharmaceuticals
• Lipid Therapeutics
• Meda
• Merck
• Mesoblast
• Mitsubishi Tanabe
• Mochida Pharmaceutical
• Morphotek
• Neovacs
• Nestle
• Norgine
• Novartis
• Ono Pharmaceutical
• Pfizer
• Procter & Gamble
• Qu Biologics
• Receptos
• RedHill Biopharma
• Salix Pharmaceuticals
• Shield Therapeutics
• Sterna Biologicals
• Synergy Pharmaceuticals
• Synthetic Biologics
• TiGenix
• Tillotts Pharma
• TopiVert
• TSD Japan
• Zeria Pharmaceutical
Market driver
• Tentative approval of late stage molecules
• For a full, detailed list, view our report
Market challenge
• Discontinuation of drugs under development and from the market
• For a full, detailed list, view our report
Market trend
• Emergence of biosimilars
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01:Executive summary
• Highlights
PART 02:Scope of the report
• Market overview
• Top-vendor offerings
PART 03:Market research methodology
• Research methodology
• Economic indicators
PART 04:Introduction
• Key market highlights
PART 05:Pipeline portfolio
• Ulcerative colitis
• Crohn's disease
• IBS
PART 06:Market landscape
• Global gastrointestinal therapeutics market
PART 07:Market segmentation by disease type
• Overview
PART 08:Global IBD therapeutics market
• Global ulcerative colitis drugs market
• Global Crohn's disease drugs market
• Market segmentation by molecule type
PART 09:Global IBS therapeutics market
PART 10:Global gastrointestinal OTC drugs market
PART 11:Geographical segmentation
• Global gastrointestinal therapeutics market by geography 2015-2020
• Gastrointestinal therapeutics market in Americas
• Gastrointestinal therapeutics market in EMEA
• Gastrointestinal therapeutics market in APAC
PART 12:Market drivers
• Increasing consumption of biologics
• Tentative approval of late stage molecules
• Development of novel therapies using innovative technologies
• Improved diagnostic tools increasing the treatment-seeking population
PART 13:Impact of drivers
PART 14:Market challenges
• Increased consumption of OTC medications
• Unknown etiology of IBD and IBS
• Discontinuation of drugs under development and from the market
PART 15:Impact of drivers and challenges
PART 16:Market trends
• Patient assistance programs
• Emergence of biosimilars
• Rise in self-medication
• Focus on regenerative medicines
• Strategic alliances and M&A
PART 17:Vendor landscape
• Competitive scenario
• Other prominent vendors
PART 18:Key vendor analysis
• AbbVie
• Johnson & Johnson
• Takeda
• Allergan
• UCB
PART 19:Appendix
• List of abbreviations
PART 20:Explore Technavio
List of Exhibits
Exhibit 01:Product offerings
Exhibit 02:Global gastrointestinal therapeutics market: Key buying criteria 2015
Exhibit 03:Global gastrointestinal therapeutics market: Key customer segments
Exhibit 04:Global ulcerative colitis therapeutics market: Pipeline portfolio
Exhibit 05:Global Crohn's disease therapeutics market: Pipeline portfolio
Exhibit 06:Global IBS therapeutics market: Pipeline portfolio
Exhibit 07:Global gastrointestinal therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 08:Global gastrointestinal therapeutics market: Factors affecting growth 2015 and 2020
Exhibit 09:Approval and patent expiries of top selling biologics
Exhibit 10:Global gastrointestinal therapeutics market 2016-2020 ($ billions)
Exhibit 11:Global gastrointestinal disorder therapeutics market segmentation: Growth cycle analysis
Exhibit 12:Five forces analysis
Exhibit 13:Global gastrointestinal therapeutics market by disease type: Revenue share 2015
Exhibit 14:Global gastrointestinal therapeutics market by disease type: Growth lifecycle analysis
Exhibit 15:Global gastrointestinal therapeutics market by disease type 2015-2020
Exhibit 16:Global IBD therapeutics market by type: Revenue share 2015
Exhibit 17:Global IBD therapeutics market by type 2015-2020
Exhibit 18:Global IBD therapeutics market segmentation: Growth lifecycle analysis
Exhibit 19:Global ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 20:Global Crohn's disease drugs market 2015-2020 ($ billions)
Exhibit 21:Global IBD therapeutics market by molecule type 2015
Exhibit 22:Biologics in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 23:Small molecules in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 24:Global IBS therapeutics market 2015-2020 ($ billions)
Exhibit 25:Drugs that underwent Rx-to-OTC switch in the US
Exhibit 26:Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
Exhibit 27:Global gastrointestinal therapeutics market by geography 2015-2020
Exhibit 28:Global gastrointestinal therapeutics market by geography 2015 and 2020
Exhibit 29:Global gastrointestinal therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30:Global gastrointestinal therapeutics market by geography: Market share 2015
Exhibit 31:Global gastrointestinal therapeutics market by geography: Disease type 2015
Exhibit 32:Global gastrointestinal therapeutics market by geography: Market growth lifecycle analysis 2015
Exhibit 33:Global gastrointestinal therapeutics market by country: Revenue and growth rate analysis
Exhibit 34:Opportunity analysis of gastrointestinal therapeutics market in Americas
Exhibit 35:Gastrointestinal therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 36:Opportunity analysis of gastrointestinal therapeutics market in EMEA
Exhibit 37:Gastrointestinal therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 38:Opportunity analysis of gastrointestinal therapeutics market in APAC
Exhibit 39:Gastrointestinal therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40:Impact of drivers and challenges on global gastrointestinal therapeutics market
Exhibit 41:Biologics for IBD: market share 2012-2022
Exhibit 42:Few biologics under development for gastrointestinal disorders
Exhibit 43:Impact of drivers
Exhibit 44:Rx-to-OTC switch: Promoters and inhibitors
Exhibit 45:Gastrointestinal therapeutics discontinued from development or market
Exhibit 46:Impact of drivers and challenges
Exhibit 47:Global gastrointestinal therapeutics market: Impact assessment of key trends
Exhibit 48:Gastrointestinal therapeutics with patient assistance programs in US
Exhibit 49:Biosimilars under development for gastrointestinal disorders
Exhibit 50:Regenerative medicines for IBD under development
Exhibit 51:Key vendors ranking 2015
Exhibit 52:Key vendors: Geographical presence
Exhibit 53:Market vendors: Competitive scenario 2015-2020
Exhibit 54:AbbVie: Profile
Exhibit 55:AbbVie: Strength analysis
Exhibit 56:AbbVie: Growth strategy matrix
Exhibit 57:AbbVie: Opportunity assessment
Exhibit 58:AbbVie: YoY growth and revenue of HUMIRA 2012-2014 ($ billions)
Exhibit 59:Johnson & Johnson: Profile
Exhibit 60:Johnson & Johnson: Strength analysis
Exhibit 61:Johnson & Johnson: Growth strategy matrix
Exhibit 62:Johnson & Johnson: Opportunity assessment
Exhibit 63:Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 64:Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 65:Takeda: Profile
Exhibit 66:Takeda: Strength analysis
Exhibit 67:Takeda: Growth strategy matrix
Exhibit 68:Takeda: Opportunity assessment
Exhibit 69:Allergan: Profile
Exhibit 70:Allergan: Strength analysis
Exhibit 71:Allergan: Growth strategy matrix
Exhibit 72:Allergan: Opportunity assessment
Exhibit 73:Allergan: Revenue of gastrointestinal therapeutics 2015 ($ millions)
Exhibit 74:UCB: Profile
Exhibit 75:UCB: Strength analysis
Exhibit 76:UCB: Growth strategy matrix
Exhibit 77:UCB: Opportunity assessment
